trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 't-dxd', 'destiny,crc,02']
 phii destiny-crc02 median 3-4 prior lines #her2+ mcrc orr 37.8% w/5.4 mg/kg vs 27.5% w/6.4 mg/kg #t-dxd w/activity also in ras mt &amp; prior her2 tx w/#adc not seen w/dual her2 targeting, 8.4% ild all grade in lower dose, median dor 5.5 mos in both #asco23 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope